Browsing by Author "Albayrak M."

Now showing 1 - 7 of 7
  • No Thumbnail Available
    Item
    Current practice of autologous hematopoietic progenitor cell mobilization in adult patients with multiple myeloma and lymphoma: The results of a survey from Turkish hematology research and education group (ThREG)
    (Elsevier Ltd, 2017) Tekgündüz E.; Demirkan F.; Vural F.; Göker H.; Özdoğu H.; Kiki İ.; Aydoğdu İ.; Kaynar L.; Erkurt M.A.; Çağırgan S.; Beşışık S.; Dağdaş S.; Koca E.; Kadıköylü G.; Gündüz E.; Yılmaz M.; Beköz H.; Ural A.U.; Baştürk A.; Arat M.; Albayrak M.; Öztürk E.; Akyol A.; Bolaman A.Z.; Nevruz O.; Özkan H.A.; Özgür G.; Altuntaş F.
    Autologous hematopoietic cell transplantation (AHCT) is an established treatment option for adult patients presenting with multiple myeloma (MM), Hodgkin lymphoma (HL) and various subtypes of non-Hodgkin lymphoma (NHL) in upfront and/or relapsed/refractory disease settings. Although there are recently published consensus guidelines addressing critical issues regarding autologous hematopoietic progenitor cell mobilization (HPCM), mobilization strategies of transplant centers show high variability in terms of routine practice. In order to understand the current institutional policies regarding HPCM in Turkey and to obtain the required basic data for preparation of a national positional statement on this issue, Turkish Hematology Research and Education Group (ThREG) conducted a web-based HPCM survey. The survey was designed to include multiple-choice questions regarding institutional practice of HPCM in adults presenting MM, HL, and NHL. The representatives of 27 adult HCT centers participated to the study. Here we report the results of this survey shedding light on the real-world experience in Turkey in terms of autologous HPCM mobilization strategies in patients presenting with MM and lymphoma. © 2017 Elsevier Ltd
  • No Thumbnail Available
    Item
    Pralatrexate experience in peripheral T-cell lymphoma: A multicenter retrospective study from Turkey
    (Zerbinis Publications, 2021) Dal M.S.; Merdin A.; Erkurt M.A.; Ekinci Ö.; Albayrak M.; Hacıoglu S.K.; Kaya A.; Dogu M.H.; Hindilerden F.; Sarici A.; Merter M.; Aras M.R.; Caglıyan G.A.; Cakar M.K.; Aydogdu I.; Kuku I.; Korkmaz S.; Ulas T.; Eser B.; Altuntas F.
    Purpose: Pralatrexate is a new generation antifolate treatment agent used for the treatment of relapsed or refractory peripheral T-cell lymphomas. This study aims to determine the general characteristics of the patients receiving pralatrexate therapy in Turkey, contributing to the literature on the effectiveness of pralatrexate therapy in peripheral T-cell lymphomas by determining the response levels of such patients to the therapy. The study also attempts to clinically examine the major side effects observed in patients during treatment with pralatrexate. Methods: The study included patients with peripheral T-cell lymphoma followed up in the hematology units of several hospitals in Turkey. Overall, 20 patients aged 18 and over were included in the study. Results: The median age at the time of diagnosis was 58.5 years. PTCL-NOS (Peripheral T-cell lymphoma, not otherwise specified) subtype was in 40% of patients, making the PTCL-NOS the most common subtype in the study. In general, most patients were diagnosed with disease at an advanced stage. Pralatrexate therapy was given to the patients at a median treatment line of 3.5. Pralatrexate dose reduction was required in only 3 patients (15%). Response to pralatrexate therapy with partial remission (PR) and above was observed in 11 (55%) of the patients. Conclusion: Pralatrexate seemed to be a promising novel treatment in relapsed refractory PTCL patients. However, patients receiving pralatrexate should be followed up carefully for skin reactions, mucosal side effects, thrombocytopenia and neutropenia. © 2021 Zerbinis Publications. All rights reserved.
  • No Thumbnail Available
    Item
    Thrombolysis with Systemic Recombinant Tissue Plasminogen Activator in Children: A Multicenter Retrospective Study; [Çocuklarda Sistemik Rekombinant Doku Plazminojen Aktivatörü ile Tromboliz: Çok Merkezli Bir Retrospektif Çalışma]
    (Turkish Society of Hematology, 2021) Zengin E.; Sarper N.; Erdem A.Y.; Al I.O.; Evim M.S.; Yaralı N.; Belen B.; Akçay A.; Yıldırım A.T.; Karapınar T.H.; Güneş A.M.; Gelen S.A.; Ören H.; Olcay L.; Baytan B.; Gülen H.; Öztürk G.; Orhan M.F.; Oymak Y.; Akpınar S.; Tüfekçi Ö.; Albayrak M.; Güneş B.T.; Canpolat A.; Özbek N.
    Objective: This study aimed to evaluate systemic thrombolysis experiences with recombinant tissue plasminogen activator (rtPA). Materials and Methods: Retrospective data were collected from 13 Turkish pediatric hematology centers. The dose and duration of rtPA treatment, concomitant anticoagulant treatment, complete clot resolution (CCR), partial clot resolution (PCR), and bleeding complications were evaluated. Low-dose (LD) rtPA treatment was defined as 0.01-0.06 mg/kg/h and high-dose (HD) rtPA as 0.1-0.5 mg/kg/h. Results: Between 2005 and 2019, 55 thrombotic episodes of 54 pediatric patients with a median age of 5 years (range: 1 day to 17.75 years) were evaluated. These patients had intracardiac thrombosis (n=16), deep vein thrombosis (DVT) (n=15), non-stroke arterial thrombosis (n=14), pulmonary thromboembolism (PE) (n=6), and stroke (n=4). The duration from thrombus detection to rtPA initiation was a median of 12 h (range: 2-504 h) and it was significantly longer in cases of DVT and PE compared to stroke, non-stroke arterial thrombosis, and intracardiac thrombosis (p=0.024). In 63.6% of the episodes, heparin was initiated before rtPA treatment. LD and HD rtPA were administered in 22 and 33 of the episodes, respectively. Concomitant anticoagulation was used in 90% and 36% of the episodes with LD and HD rtPA, respectively (p=0.0001). Median total duration of LD and HD rtPA infusions was 30 h (range: 2-120 h) and 18 h (2-120 h), respectively (p=0.044). Non-fatal major and minor bleeding rates were 12.5% and 16.7% for LD and 3.2% and 25.8% for HD rtPA, respectively. At the end of the rtPA infusions, CCR and PCR were achieved in 32.7% and 49.0% of the episodes, respectively. The most successful site for thrombolysis was intracardiac thrombosis. HD versus LD rtPA administration was not correlated with CCR/PCR or bleeding (p>0.05). Conclusion: Systemic thrombolytic therapy may save lives and organs effectively if it is used at the right indications and the right times in children with high-risk thrombosis by experienced hematologists with close monitoring of recanalization and bleeding. © 2021, Turkish Society of Hematology. All rights reserved.
  • No Thumbnail Available
    Item
    The clinicopathological features and survival of Castleman disease: A multicenter Turkish study
    (Verduci Editore s.r.l, 2022) Yildiz J.; Bagci M.; Sayin S.; Kaya A.; Yilmaz F.; Ekinci O.; Dal M.S.; Basturk A.; Aydogdu I.; Albayrak M.; Dogan A.; Erkurt M.A.; Korkmaz S.; Ulas T.; Eser B.; Altuntas F.
    Objective: In this study, we aimed to investigate the clinicopathological features and survival of CD, which is quite rare and has many unknowns. Patients and Methods: This study was conducted by retrospectively evaluating patients diagnosed with CD in six different centers in Turkey. Results: The median age of 33 patients included in the study was 49 and 51.5% (n = 17) of these patients were women. 18 (54.5%) patients were in the hyaline vascular subtype and most of the patients were UCD (n = 20, 60.6%). The most common involvement region was head and neck (n = 19, 57.5%). The UCD group was younger than the MCD group (p=0.027). Visceral lymph node involvement was higher in MCD than in UCD (p=0.001). Similarly, it was observed that there was more hepatomegaly (p=0.035) and splenomegaly (p=0.013) in the MCD group. During the median 19.5 months follow-up period, there were no patients who died. Conclusions: It was observed that UCD and MCD are different clinical entities. Promising survival times can be achieved with surgical and systemic treatments in both subtypes of this extremely rare disease. However, this result should be supported by well-designed prospective comprehensive studies. © 2022 Verduci Editore s.r.l. All rights reserved.
  • No Thumbnail Available
    Item
    Real-world data on the effectiveness and safety of Ixazomib-Lenalidomide-Dexamethasone therapy in relapsed/refractory multiple myeloma patients: a multicenter experience in Turkey
    (Taylor and Francis Ltd., 2023) Bakırtaş M.; Dal M.S.; Yiğenoğlu T.N.; Giden A.O.; Serin I.; Başcı S.; Kalpakci Y.; Korkmaz S.; Ekinci O.; Albayrak M.; Basturk A.; Ozatli D.; Dogu M.H.; Hacıbekiroglu T.; Çakar M.K.; Ulas T.; Miskioglu M.; Gulturk E.; Eser B.; Altuntas F.
    A multicenter, retrospective, observational study was conducted to explore effectiveness and safety of ixazomib plus lenalidomide with dexamethasone (IRd) in relapsed/refractory multiple myeloma (RRMM) patients following at least ≥ two lines of therapy. Patients’ treatment responses, overall response rate, progression-free survival rate, and adverse events were recorded. Mean age of 54 patients was 66.5 ± 9.1 years. There were 20 patients (37.0%) with progression. Median progression-free survival was 13 months in patients who received a median of three therapy lines in a 7.5-month follow-up period. Overall response rate was 38.5%. Of 54 patients, 19 (40.4%) had at least one adverse event, and nine (19.1%) had an adverse event of at least grade 3 or more. Of 72 adverse events observed in 47 patients, 68% were grade 1 or 2. Treatment was not stopped in any patient due to adverse events. IRd combination therapy was effective and safe in heavily treated RRMM patients. © 2023 Edizioni Scientifiche per l'Informazione su Farmaci e Terapia (Italian Society of Chemotherapy).
  • No Thumbnail Available
    Item
    International Forum: The Turkish perspective on apheresis activity: The Turkish apheresis registry report
    (Elsevier Ltd, 2023) Ozatli D.; Giden A.O.; Erkurt M.A.; Korkmaz S.; Basci S.; Ulas T.; Turgut B.; Yigenoglu T.N.; Hacibekiroglu T.; Basturk A.; Dal M.S.; Namdaroglu S.; Hindilerden F.; Hacioglu S.K.; Cagliyan G.A.; Ilhan G.; Kacmaz M.; Uysal A.; Merter M.; Ekinci O.; Dursun F.E.; Tekinalp A.; Demircioglu S.; Sincan G.; Acik D.Y.; Akdeniz A.; Ucar M.A.; Yeral M.; Ciftciler R.; Teke H.U.; Umit E.G.; Karakus A.; Bilen Y.; Yokus O.; Albayrak M.; Demir C.; Okan V.; Serefhanoglu S.; Kartı S.; Ozkurt Z.N.; Eser B.; Aydogdu I.; Kuku I.; Cagirgan S.; Sonmez M.; Ozet G.; Altuntas F.
    Therapeutic apheresis is an extracorporeal treatment that selectively removes abnormal cells or harmful substances in the blood that are associated with or cause certain diseases. During the last decades the application of therapeutic apheresis has expanded to a broad spectrum of hematological and non-hematological diseases due to various studies on the clinical efficacy of this procedure. In this context there are more than 30 centers performing therapeutic apheresis and registered in the apheresis database in Turkey. Herein, we, The Turkish Apheresis Registry, aimed to analyze some key articles published so far from Turkey regarding the use of apheresis for various indications. © 2023 Elsevier Ltd
  • No Thumbnail Available
    Item
    Common viral respiratory infections in children with cancer during the COVID-19 pandemic: a multicenter study from Türkiye
    (Turkish National Pediatric Society, 2024) Kaçar D.; Kebudi R.; Özyörük D.; Tuğcu D.; Bahadır A.; Özdemir Z.C.; Özgüven A.A.; Orhan M.F.; Yıldırım A.T.; Albayrak C.; Kartal İ.; Sarı N.; Tokgöz H.; Albayrak M.; Ayhan A.C.; Eroğlu N.; Aydın S.; Üzel V.H.; Zülfikar B.; Yıldırım Ü.M.; Büyükavcı M.; Gülen H.; Töret E.; Bör Ö.; Özbek N.Y.; İlhan İ.E.; Yaralı N.
    Background. Microbiologic confirmation of respiratory tract infections gained importance during the coronavirus disease 2019 (COVID-19) pandemic. This study retrospectively evaluated seasonal distribution, clinical presentation, and complications of respiratory viral infections (RVIs) other than COVID-19 in children with cancer during and after the pandemic lockdown. Methods. Two hundred and sixty-five inpatient and outpatient RVI episodes in 219 pediatric cancer patients confirmed by multiplex reverse transcriptase polymerase chain reaction (RT-PCR) panels from 13 centers were enrolled. Results. Eighty-six (32.5%) of the total 265 episodes occurred in 16 months corresponding to the lockdowns in Türkiye, and the remaining 67.5% in 10 months thereafter. Human rhinovirus/enterovirus (hRE) (48.3%) was the most common agent detected during and after lockdown. Parainfluenza virus (PIV) (23.0%), influenza virus (9.8%), and respiratory syncytial virus (RSV) (9.1%) were the other common agents. The 28.7% of episodes were lower respiratory tract infections (LRTIs), and complications and mortality were higher than upper respiratory tract infections (URTIs) (25.0% vs 5.3%). Bacteremia was identified in 11.5% of culture-drawn episodes. Treatment delay in one-third and death within four weeks after RVI in 4.9% of episodes were observed. Conclusion. During the pandemic, fewer episodes of RVIs occurred during the lockdown period. Respiratory viruses may cause complications, delays in treatment, and even death in children with cancer. Therefore, increased awareness of RVIs and rapid detection of respiratory viruses will benefit the prevention and, in some cases, abrupt supportive and some antiviral treatment of RVI in children with cancer. © 2024, Turkish National Pediatric Society. All rights reserved.